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Abstract: New technological concepts have been evolving to manage the relative poor prognosis of lung cancer. 
Brachytherapy is becoming an option for both unresectable and early resectable lung cancer. Three-dimensional 
ultrasound (US) of lung tumours and image-guided minimally invasive robotics-assisted brachytherapy are feasible for 
dosimetry planning and management of lung tumours. The present article reviews the current knowledge of lung 
brachytherapy and discusses its potential in future management of lung cancer. 
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INTRODUCTION 
 Lung cancer is the leading cause of cancer death in men, 
and has surpassed breast cancer as the most frequent cause of 
death in women [1]. Surgical resection is the treatment of 
choice, but only one third of patients who present with early 
disease are eligible for a curative resection [2]. Open surgery 
provides ready access and optimal visualization of body 
cavities, however, it has a higher rate of morbidity compared 
to minimally invasive techniques. Other options need to be 
developed. Brachytherapy is a form of radiation therapy 
delivered by the direct placement of a radioactive source into 
a tumour or tumour bed. It provides an option that avoids 
major surgery, chemotherapy, and is not susceptible to the 
uncertainty of tumour motion while the patient receives 
external beam radiation. It also avoids conventional multiple 
external beam radiation fractions that occur over several 
weeks. Brachytherapy also has theoretical advantages 
including: i) it is easily adapted to the shape and size of 
tumour, ii) it delivers a higher tumour dose compared to 
external beam irradiation, and iii) the delivered radiation 
dose decreases rapidly outside the treated tumour volume, 
significantly sparing the normal tissue in the tumour vicinity. 
LUNG CANCER BRACHYTHERAPY 
 Endobronchial and/or intraoperative lung brachytherapy is 
effective and has a good curative potential in patients with 
localized tumours of small to moderate size, well defined and 
easily accessible. Large tumours, multiple lesions, or the pre-
sence of lymph node metastases precludes curative treatment by 
brachytherapy. In selected cases, quick and effective palliation 
may be obtained by an endobronchial outpatient procedure. 
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 Brachytherapy techniques and approaches can be tailored 
to the clinical situation and can be administered over a very 
short period of time (high dose rate), or over a protracted 
time (low dose rate). Table 1 shows the commonly use 
isotopes in brachytherapy. 
 There are two common brachytherapy techniques for 
lung cancer: Endobronchial Brachytherapy and Interstitial 
Brachytherapy. The details of these two techniques are 
discussed below. 
Endobronchial Brachytherapy 
 Endobronchial treatment is the most common lung 
brachytherapy technique. Radiation therapy is delivered from 
within the trachea or bronchus lumen by placement of one or 
two afterloading applicators. The applicators, sometimes 
referred to as catheters, typically have a 5 or 6 French 
external diameter. A guidewire is often used to pass directly 
through the operating channel of a fibre optic bronchoscope 
and be threaded through the involved airway. Care must be 
taken to slowly advance the applicator over the guidewire, 
preferably under direct visual or fluoroscopic control. After 
placement of the brachytherapy catheter, the bronchoscope is 
removed and “dummy” seeds (an inactive strand of radio-
opaque marker pellets) are inserted within the applicator. An 
orthogonal set of chest radiographs (anterior-posterior and 
cross-table lateral) are obtained. The target is identified on 
the films using the visual information obtained that day by 
the bronchoscopist combined with previous radiological or 
bronchoscopic findings. The distal extent of the tumour 
cannot always be visualized by the bronchoscopist and must 
often be estimated from previous computerized tomography 
scans, chest radiographs, etc. Brachytherapy is delivered to 
the endobronchial tumour length with a 1–2 cm proximal 
and distal margin. The dummy seeds are then removed from 
the catheter and replaced with an inner applicator with 
radiation source of either Low Dose Rate (LDR) or High 
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Dose Rate (HDR) inner applicator. HDR remote afterloading 
machines contain a microprocessor that controls the transfer 
of the source down the flexible inner applicator to the 
specified region, and withdraws it automatically into the 
machine when treatment is complete. Treatment is delivered 
in a shielded room where the patient and the patient’s vital 
signs and oxygen saturation can be monitored from outside 
the room with the use of video equipment. The remote 
afterloading treatment can be interrupted at any time if 
necessary. 
Interstitial Brachytherapy 
 Several investigators have described the technical aspects 
of permanent interstitial brachytherapy, the placement of 
radioactive source into the tumour or target region where no 
lumen exists [3–7]. This can be accomplished 
intraoperatively, transbronchially, or percutaneously. 
Isotopes such as Iodine (I-125), Palladium (Pd-103) and 
Gold (Au-198) which have low energy gamma rays, small 
physical size, and short half-lives are often used. Mick 
applicators are commercially available to insert the seeds 
manually one by one into the target region. However, the 
risk of subsequent seed movement has led many 
brachytherapists to suggest, depending on the clinical 
situation, that seeds be in the form of a strand with a Vicryl
®
 
carrier which can be woven into a Dexon
®
 mesh and secured 
to the tumour bed [5]. Nori et al. [5] have described the 
intraoperative technique of sandwiching iodine seeds 
between sheets of Gelfoam and then securing these in place 
with Dexon
®
/Vicryl
®
 mesh. In their experience, the seeds 
have remained in site despite the fact that the mesh and 
Gelfoam are absorbed within the surrounding tissues within 
6–8 weeks. 
 Brachytherapy can be given in either HDR or in LDR as 
presented below. A review the clinical results of 
brachytherapy is also presented. 
HDR Brachytherapy 
 HDR brachytherapy has been defined as brachytherapy 
capable of delivering more than 12 Gy/h (>0.2 Gy/min) [8]. 
The isotopes most commonly used include Cobalt (Co-60), 
Caesium (Cs-137), and Iridium (Ir-192). Endobronchial 
HDR brachytherapy uses a flexible bronchoscope to place an 
intraluminal treatment applicator at the location of the 
tumour to provide higher radiation dose at the center of the 
tumour than at the periphery. This reduces the effect of the 
radiation on the surrounding tissue [9]. HDR brachytherapy 
has been used as an alternative to, and in combination with, 
external beam radiation therapy for palliation of symptoms 
such as dyspnea, cough, chest pain, and hemoptysis in 
nonsmall cell lung cancer (NSCLC) [10]. Quality of life 
assessment in HDR has been reported in randomized trials 
including Langendijk et al. [11] the European Organization 
for Research and Treatment of Cancer (EORTC) general 
questionnaires, Sur et al. [12,13] the National Cancer 
Institute Common Toxicity Criteria, Stout et al. [14] 
Rotterdam Symptom Checklist and Hospital Anxiety and 
Depression scale. In general HDR relieves and improves 
symptoms of dyspnea, atelectasis, and chest pain. In 
particular HDR is most valuable in patients previously 
treated with external beam radiation therapy and 
symptomatic for recurrent disease due to endobronchial 
obstruction. The general recommended dose for HDR in 
symptom control is 1000 cGy at 1 cm from central axis 
given in a single fraction, with 2 cm proximal and distal 
margin [10]. Most tumours either decreased in size or there 
was a reduction in pain. However, complications such as 
pneumothorax, and hemoptysis have been described [10]. 
 An electromagnetic navigated bronchoscopic approach to 
a small peripheral tumour has recently been described by 
Harms et al. [15]. A single patient with medically inoperable 
NSCLC in the right upper lobe was treated with external-
beam radiotherapy (50 Gy) and navigated endoluminal 
brachytherapy (15 Gy). Bronchoscopy was performed with 
an electromagnetic navigation using a microsensor mounted 
on the tip of a dedicated catheter placed within the working 
channel of a bronchoscope. Endobronchial ultrasound 
(EBUS) was performed to confirm the exact position in the 
center of the lesion. HDR brachytherapy (370 GBq Ir-192) 
was applied. Complete remission was found during follow-
up (12 months). HDR brachytherapy has also been delivered 
to lung cancers using a percutaneous route [16–20]. Ricke 
Table 1. Common Isotopes used in Brachytherapy 
 
Isotopes T1/2 ?-Ray (MeV) ?-Ray (Avg.MeV) T(R/mCi/hr@1cm) HVL (cmPb) 
60Co 5.26y 1.25 0.093 13.07 1.03 
90 Sr 28y - 0.196 - - 
98mTc 6.03h 0.141 0.014 0.6 - 
103Pd 16.97d 0.022 - 1.48 0.001 
125I 59.4d 0.028 0.036 1.33 0.003 
131I 8.06d 0.08-0.723 0.192 2.24 0.3 
137Cs 30.0y 0.662 0.186 3.28 0.6 
192Ir 74.0d 0.36 0.181 4.6 0.26 
198Au 2.7d 0.412 0.315 2.38 0.3 
226Ra 1604y 1.03 - 8.25 0.8 
T –Exposure rate constant; T1/2 – Half –life; HVL- Half value layer; y-year, d-day, h-hour. 
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and coworkers [19] reported a pilot study of 30 patients with 
interstitial HDR brachytherapy. In their study cohort the 
maximum tumour size was 4 cm and the brachytherapy 
catheter was positioned under CT fluoroscopy. A single 
fraction of 20 Gy was delivered to the tumour. Although the 
follow up was short (median 5 months) local tumour control 
was 97%. CT guided interstitial brachytherapy was safe. 
 Brachytherapy has been used by several investigators as 
a boost either before, during or after external beam radiation 
in the definitive treatment of unresectable NSCLC. The 
experience of HDR brachytherapy boost is extensive in the 
literature [21–27]. Patients selected for definitive external 
beam radiation and a brachytherapy boost were usually 
medically fit patients with centrally located stage IIIA or 
IIIB tumours, without weight loss in 6 months leading up to 
diagnosis. External beam radiation dose ranged from 50–70 
Gy with HDR boost of 2.7–10 Gy per fraction at 1–5 
fractions over a 1–2 week fraction interval. Response to 
brachytherapy was assessed by bronchoscopy 1–3 months 
from completion of treatment. As expected, initial patient 
performance status, tumour size and stage, and radiation 
dose are important predictors of outcome [22, 26, 28]. 
Aygun and colleagues [22] observed that response rates 
favour patients with tumours not visible radiographically. 
Higher combined doses of brachytherapy and external beam 
radiation have been associated with an increased 
endobronchial response. No complications were seen in 
patients treated to a dose of 70 Gy, as compared to a 24% 
complication rate seen in patients receiving more than 85 Gy 
[27]. Common complications are hemoptysis, bronchial 
stenosis, and bronchitis, with tracheoesophageal fistula being 
less commonly reported in the literature. Differentiating 
treatment complications from tumour progression is often 
challenging as autopsies have been done in only a small 
proportion of patients undergoing brachytherapy. For 
tumours in the mainstem or upper lobe bronchus, there 
appears to be an increased frequency of hemorrhage for 
right-sided (25%) as opposed to left-sided lesions (25% and 
10%), perhaps due to the proximity of the treatment catheter 
to the pulmonary artery [22]. 
LDR Brachytherapy 
 LDR brachytherapy is another form of radiation therapy 
with dose rates ranging from 0.1 cGy/hr to 50 cGy/hr. The 
radioisotopes most commonly used include Iodine (I-125), 
Palladium (Pd-103) and gold (Au-198), and when placed 
inside titanium shells are called seeds. They can be in the 
form of individual seeds or joined together to form a strand. 
The overall size of the seed can vary slightly depending on 
the application. 
 Hilaris and Martini reviewed the Memorial Sloan-
Kettering Cancer Center experience in over 1,000 patients 
that received intraoperative (LDR) brachytherapy via an 
open thoracotomy [20]. The use of interstitial brachytherapy 
as potential curative and palliative treatment of superior 
sulcus tumours have been reported extensively [29–31]. 
Results of 129 patient case series have been reported by the 
Memorial Sloan-Kettering Cancer Center with superior 
sulcus tumour treated with I-125 for permanent implantation 
or temporary implantation of Ir-192. The overall survival of 
this series was encouraging with 25% survival rate at 5 years 
favouring patients with adenocarcinomas, negative 
mediastinal involvement, preoperative radiation therapy 
followed by surgery. Radiation toxicity includes mild 
dysphagia for patients who received mild dose of pre-
operative radiation therapy. Selective intraoperative 
brachytherapy has been reported by Armstrong et al. [32]. In 
their case series of 10 patients receiving intraoperative 
brachytherapy for residual disease, in spite of the advanced 
disease in the brachytherapy group, actual progression free 
survival at 2 years and 5 years was 66% and 55% 
respectively. Intraoperative LDR lung brachytherapy alone 
or in combination with other local and systemic therapies 
suggest that a subgroup of patients with gross or microscopic 
disease left in the thorax after incomplete resection or biopsy 
only, can be controlled locally [33]. 
 Interstitial brachytherapy is not used frequently in 
clinical practice. This may be due to difficulty in gaining 
expertise with interstitial techniques, as compared to external 
beam treatment planning or even endobronchial 
brachytherapy. Endobronchial brachytherapy is more widely 
practiced in many cancer centers [10, 34]. Brachytherapy-
related complications have been graded and management has 
been proposed [25, 35]. 
 Brachytherapy-related hemoptysis has been graded as 
massive (fatal) or not massive, and management is the same 
as hemoptysis from other causes. Treatment includes bed 
rest, codeine, fluid replacement, avoidance of anticoagulants, 
selective lung insulation and bronchial artery embolization. 
A brachytherapy related bronchitis grading system to enable 
comparison of complication between various dose-
fractionation regimens has been proposed by Speiser and 
Spratling [25] and management is summarized in Table 2. 
INTERSTITIAL BRACHYTHERAPY – A CHALLENGING 
PROCEDURE 
 Interstitial brachytherapy allows more precise delivery of 
radiation and easier adaptation to the tumour shape than is 
possible with external radiation [20, 36], and a higher dose 
can be delivered to the tumour volume with less damage to 
the normal lung. The seeds are implanted into cancerous 
tissue using long and hollow needles, which have small outer 
diameters and at least one sharp end to allow penetration 
through the tissue. The seeds are manually loaded into the 
needle barrel and are spaced from each other by one or more 
inert spacers that are implanted together with the seeds. A 
small amount of bone wax is placed on the tip of the implant 
needles to prevent the seeds from falling out and to prevent 
the tissue from entering the hollow needle. A stylet inserted 
in the needle behind the last seed is used to release the bone 
wax and drop the seeds. 
 During the brachytherapy procedure, the goal is to 
implant the seeds into the tumour such that they are 
uniformly distributed in a particular pattern selected to 
ensure that the tumour receives the appropriate dose. In 
general, a series of aligned seeds is introduced with each 
insertion of the needle. To achieve this goal, each needle 
must be accurately inserted into the tissue following a 
particular path and reaching a specified depth. Accurate 
placement is required to avoid over-radiated and under-
radiated areas, and to ensure that all the seeds are located 
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within the target region. Once the needle has accurately 
reached the target location, the needle barrel is retracted 
towards the stationary stylet, thereby dropping from the tip 
of the needle. 
 This procedure is commonly performed in the prostate, 
for which coordinate grids are often used to guide the needle 
insertion in order to improve the accuracy of needle 
placement, while real-time ultrasound images are used to 
guide the needles to the desired depth. In a common prostate 
brachytherapy procedure, 80–100 seeds are implanted into 
the prostate using between 20 and 25 needles. 
 The biggest challenge in delivering radiation therapy is 
achieving an accurate dosage of radiation. Since the entire 
treatment is very complex, careful consideration of the 
planning and delivery is required in order to optimize results 
and minimize side effects [37]. During a lung brachytherapy 
procedure, this challenge translates into accurately placing 
the seeds, since small deviations in seed alignment can create 
significant areas of over-dosage and under-dosage. Some of 
the causes for seed misplacement are as follows: 
I. Difficulty in accessing the surgical site due to the 
presence of bone structures (rib cage), major nerves, 
or blood vessels. Significant clinical expertise is 
needed to properly access the surgical site [38]. 
II. Difficulty in locating the needle prior to the 
penetration, and in achieving the proper penetration 
depth. 
III. During needle barrel retraction, difficulty in holding 
of the stylet stable relative to the needle. Small 
unintended movements of the stylet relative to the 
barrel can result in inaccurate seed placement and a 
reduction in the effectiveness of the treatment. 
IV. Changes in tissue location and size between dose 
planning and seed implantation [39]. 
V. Patient movement during the procedure due to tissue 
shift, breathing, heartbeat, or swelling of the organs. 
 Furthermore, in traditional brachytherapy procedure the 
surgical personnel are exposed to the radiation source for a 
large amount of time. Manual insertion of the needles can 
take a long time, since it sometimes requires as many as 20 
insertions prior to achieving accurate placement. 
 The use of LDR encapsulated I-125 seeds with its 60 
days half-life and low energy photon make interstitial 
brachytherapy more practical. It greatly reduces the radiation 
outside of the treatment volume and minimizes the medical 
and nursing staff exposure. However, the intraoperative 
radiation exposure to the surgeon and radiation oncologist 
and the need for a large open thoracotomy with only a 
modest survival advantage has hindered its clinical 
acceptance. 
 There is only limited experience with LDR interstitial 
brachytherapy under bronchoscopic, fluoroscopic and CT 
guidance [2, 20, 40–42]. Although the CT-guided 
percutaneous approach is feasible, it is limited to small and 
soft tumours in the periphery of the lung, and the optimum 
radiation dose distribution frequently cannot be achieved due 
to the bony structures in the chest wall that inhibits precise 
seed implantation. The risk of injury to proximal mediastinal 
structures, bleeding, and lung collapse, also limits this 
technique to only small tumours adjacent to the chest wall. 
ROBOTICS-ASSISTED MINIMALLY INVASIVE 
THORACIC SURGERY 
 Minimally invasive surgery (MIS) employs the use of 
instruments through small incisions in the patient’s chest or 
abdomen to remove cancers. The procedure relies on 
endoscopic video images for guidance, and the surgeon for 
instrument manipulation. Procedure-related intraoperative 
complications can be dealt with immediately. Compared 
with a thoracotomy, MIS or video-assisted thoracoscopic 
surgery (VATS) offers patients a shorter length of hospital 
stay, less pain, and a quicker recovery, without 
compromising the adequacy of the operation [43, 44]. 
Thousands of VATS lobectomies have been performed since 
it was pioneered in 1992, but currently most lobectomies are 
still performed via a thoracotomy. Although most 
lobectomies could be performed as VATS, less than 5% are 
currently performed this way due to limitations of minimal 
access, restricted manoeuvrability of instruments, and 
impaired two-dimensional (2D) visualization. The 
techniques are difficult to learn and therefore not used as 
often. 
 Surgical robots have been shown to improve MIS 
efficiency by providing superior three-dimensional (3D) 
Table2. Grading of Radiation Bronchitis and Management 
 
Grading Radiation Bronchitis Treatment 
Grade I 
Mild mucosal inflammatory response with swelling, characterized by a thin, whitish, 
circumferential membrane. No significant luminal obstruction.  
Observation 
Grade II 
White fibrinous membrane with exudation causing systems such as cough and /or obstructive 
problems  
Steroids-oral and /or aerosol Fluconazole 
Saline-diluted bronchodilators 
Narcotic cough suppressants 
Grade III 
Severe inflammatory response with marked membranous exudate. Multiple debridement or 
other interventions required to reestablish full lumen of airway. 
Balloon or bougie dilatation 
Laser photoresection 
Debridement 
Stents 
Grade IV 
Greater degree of fibrosis with resulting circumferential stenosis leading to a decrease in 
luminal diameter. 
Same as in Grade III 
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magnification, enhanced dexterity, and improved precision 
by tremor filtration and motion scaling [45–48]. To the 
surgeon, surgical robots also offer improved ergonomics, 
instrument dexterity during VATS, and the opportunity to 
operate via telesurgery at a safer distance from the 
radioactive source [49]. Surgical use of robotics, or 
computer-assisted surgical systems (CAS), has evolved over 
the last 10 years for the treatment of chest diseases, however, 
significant development has really only occurred in the last 3 
to 4 years. Moreover, because of this modest experience, 
robotic thoracic procedures currently take more time than 
non-robotic cases and, thus, are more expensive. The 
surgical learning curve appears to be steep, especially for the 
more complex procedures [50]. As surgeons gain greater 
experience and the complexity and cost of the equipment are 
reduced, we should expect to see greater use of CAS in 
thoracic surgery. 
 The ZEUS
®
 surgical system was the world’s first and 
only telesurgical robotic platform able to provide surgical 
care at a distance. It had the potential to interface with 
surgeons in any part of the world and beyond. It was an 
ergonomically optimal environment that interfaced with a 
networked operating room and surgical devices. It was 
developed and manufactured by Computer Motion, Inc. 
Computer Motion merged with its competitor, Intuitive 
Surgical, Inc. and ZEUS robotic platform was replaced by 
the da Vinci
®
 platform. 
 The da Vinci Surgical System combines superior 3D 
visualization along with greatly enhanced dexterity, 
precision, and control, in an intuitive, ergonomic interface 
with breakthrough surgical capabilities [46–48, 51]. By 
enhancing surgical capabilities, the robots reduce trauma to 
the body, reduce blood loss and need for transfusions, 
decrease post-operative pain and discomfort, lower the risk 
of infection, decrease hospital stay, allow for faster recovery 
and return to normal daily activities, reduce scarring, and 
improve cosmesis. The robots also allow the surgeon to 
perform minimally invasive procedures more safely, by 
allowing immediate access to vital structures and the ability 
to repair injuries that may occur during the brachytherapy 
procedure. 
ADJUVANT BRACHYTHERAPY FOR LUNG CANCER 
 The recent increase in MIS has also renewed an interest 
in the role of adjuvant brachytherapy for lung cancer [52–
59]. Following resection of small lung tumours (T1N0), 
intraoperative I-125 seeds have been implanted with Vicryl
®
 
mesh along the resection margins [52, 53, 57]. The technique 
appears to be safe and appears to reduce local tumour 
recurrence rates, but long-term results are required. Pisch et 
al. have reported on the ability of da Vinci system to suture 
in brachytherapy seeds into a porcine lung [56]. MIS wedge 
resections were performed in the upper and lower lobes. 
Dummy I-125 seeds embedded in absorbable sutures were 
sewn into the resection margin with the aid of the da Vinci 
system without complications. The robotic technology 
allowed direct placement of radioactive seeds into the 
resection margin by endoscopic surgery. This renewed 
enthusiasm for lung brachytherapy has resulted in a multi-
institutional randomized phase III study of sublobar 
resection versus sublobar resection plus brachytherapy in 
high-risk patients with nonsmall cell lung cancer sponsored 
by the American College of Surgeons Oncology Group 
(ACOSOG 4032) [60]. This study is now closed accrual and 
results are pending. 
 It is believed that earlier detection of lung cancer should 
translate into more effective treatment. Lung cancer 
screening has been revived with various reports showing an 
advantage of low-dose CT over chest radiographs in 
detecting smaller size tumours and at an earlier stage [61]. 
Studies have found that eighty percent of all the tumours 
found were of stage I, with an estimated 8-year cure rate for 
resected lung cancers of 95% [62, 63]. This suggests that a 
higher proportion of deaths from lung cancer can be 
prevented by CT screening followed by early resection [63, 
63]. The gold standard therapy for NSCLC is a lobectomy, 
while lesser resections are reserved as a compromise 
operation for high-risk patients [64, 65]. Earlier studies have 
suggested that sublobar resections for stage I tumours are 
complicated by increased locoregional recurrence rates [64, 
66]. The increased identification of small NSCLC tumors by 
CT scan is leading many surgeons to question the 
appropriateness of lobectomy for these tumors. There is an 
increasing interest by many surgeons to use sublobar 
resection as the new standard for patients with small 
peripheral lung cancers [67]. Intentional sublobar resection 
for small lung cancers (T1N0) has been performed using 
minimally invasive techniques with equivalent results [68–
74]. Recently, intraoperative brachytherapy on the resection 
staple line has been shown to significantly decrease the local 
recurrence rates associated with these limited resections [52, 
54, 55, 57, 59]. Our experience with intraoperative 
brachytherapy reveals this technique can achieve 
considerable lung volume sparing for irradiation to normal 
tissue with less than 2% lung volume receiving 20 Gy
1
 (Fig. 
1). Future directions in the management of early lung cancer 
will include MIS surgery combined with brachytherapy. 
ROBOTICS-ASSISTED MINIMALLY INVASIVE 
BRACHYTHERAPY FOR LUNG CANCER 
 The future of lung cancer therapy may include the 
placement of individual brachytherapy seeds minimally 
invasively into lung cancers using a robotics-assisted 
brachytherapy seed delivery system. The prerequisites for 
such an approach are: i) a method to localize the tumour 
intraoperatively; ii) a means of tracking and guiding the 
needle in real time; iii) 3D images of the tumour from which 
the dosimetry will be planned (based on the tumour 
contours); and iv) a brachytherapy seed delivery device for 
the robot. Here we shall discuss the prerequisites of the 
robotics-assisted brachytherapy approach. 
Lung Tumour Localization 
 For minimally invasive brachytherapy to be performed in 
the lung, it is imperative that some form of image guidance 
be incorporated for instrument tracking and tumour 
localization. Tumours that are deep within the lung cannot be 
seen with the thoracoscope. The procedure is performed 
                                                
1Yu E, Lewis C, Malthaner RA. Intra-operative brachytherapy of localized 
Non-small cell Lung Cancer. Unpublished data. 
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through small incisions making it impossible to palpate the 
nodules manually [75]. Current tumour localization 
techniques include methylene blue staining and the insertion 
of a hook wire [76-81]. These methods have been found to 
be cumbersome, have a high failure rate, and increase 
medical risks and litigation [82-84]. A method that can 
reliably localize lung nodules intraoperatively during a 
minimally invasive procedure is needed. Although lung 
tumours may be readily seen using CT imaging, CT scanners 
are not available in operating rooms for intraoperative use 
and there is often a delay of several months between a 
preoperative CT scan and the actual surgical procedure. 
From a global perspective, intraoperative ultrasound imaging 
appears to be the modality of choice. Ultrasound does not 
expose the patient to radiation as a CT does, and it can 
achieve real-time dependable dose plans for the delivery of 
brachytherapy. MIS ultrasound probes are now available 
from many manufacturers, enabling its use in guiding 
minimally invasive thoracic surgeries. 
Needle Tracking and Guidance 
 Much effort has been put into overlaying real-time 
navigation information into preoperative information to 
serve as image guidance during procedures. A tracking 
device can be attached to the tool and its position displayed 
on the preoperative image (e.g. MRI, PET, CT). Kevin 
Cleary’s group at Georgetown University has developed a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Intraoperative lung brachytherapy. (A and B) Chest x-ray (PA and lateral films) of a stage I NSCLC patient with limited pulmonary 
capacity post sublobar resection and intraoperative brachytherapy. (C) Post intraoperative brachytherapy CT –simulation and treatment 
reveals I-125 seeds in place. Total dose prescribed was 100 Gy (blue isodose line). Isodose lines are also displayed for 50 Gy (yellow) and 
200 Gy (red). (D) 3D display of the Planning Target Volume (PTV) demonstrating dose coverage by the 100 Gy prescription. 
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system for surgical assistance incorporating magnetic 
tracking and CT image overlay for targeting internal organs 
such as the liver [85]. Roeddiger’s group in Germany [86] 
has studied virtual reality image overlays for brachytherapy. 
Their work uses preoperatively acquired image data that is 
then displayed together with the position of the tracked 
instrument on a transparent overlay that can be put on top of 
the patient. An ongoing challenge with the static 
preoperative CT images is the reduced navigational accuracy 
due to respiratory motion. Strides have been made with 
electromagnetic tracking for abdominal interventions [87-
91]. However, no system exists today that can compensate 
for lung motion around lung tumours. 
 Recent advances in electromagnetic tracking systems 
have led to the miniaturization of the sensors and better 
immunity to nearby metallic objects. For example, the 
microBIRD™ tracking system (Ascension Technology 
Corporation) features a 6 degree-of-freedom DC magnetic 
tracker with a sensor diameter of just 1.3 mm. An 
electromagnetic transmitter situated outside of the body 
generates a weak spatially varying magnetic field that can be 
measured by the sensor to dynamically compute position and 
orientation. Field distortions caused by nearby conductive 
metals, which significantly affected earlier AC systems, have 
been minimized using DC pulses. 
Brachytherapy Treatment Planning 
 CT simulation has been the standard for treatment 
planning in many modern radiation therapy centres; 
however, CT simulation is not readily available 
intraoperatively in most countries. The literature on 3D 
ultrasound simulation with permanent brachytherapy seed 
implantation treatment planning in lung cancer is limited 
[92]. The number of permanent seeds used in a given tumour 
volume and the angle of brachytherapy needle entry for a 
given tumour mass have yet to be defined. The dosimetry 
plan for MIS interstitial brachytherapy seeds in lung tumours 
is unknown. Standard needle templates used in prostate 
brachytherapy are not usable for intrathoracic tumours due to 
the bony rib cage and the restriction of only one entry port as 
a component of MIS. New approaches need to be developed. 
Brachytherapy Seed Delivery System 
 Many researchers have been working on ways to improve 
brachytherapy procedures. Currently the most common 
usage of brachytherapy is in the treatment of prostate cancer 
and hence many of the developments have focused on this 
area. The contributions found in the literature can be 
summarized as follows: control of the relative motion 
between the hollow needle and the plunger [93]; accurate 
positioning and orienting of the needle prior to penetration 
[94-96]; drivers for needle penetration [37, 96, 97]; real-time 
image guidance during needle insertion [85, 94-98]; force 
feedback during needle insertion [96-99]; and tissue motion 
compensation [100-103]. However, none of these devices is 
currently available on the market due to their complexity and 
lack of regulatory approval for clinical use. Additionally, 
they are designed only for percutaneous needle insertion, and 
most have been designed specifically to treat tumours 
located in the prostate. The process of implanting seeds 
within lung cancerous tissue could greatly benefit from the 
use of minimally invasive robotic systems; however, an 
instrument that can be attached to these systems for 
brachytherapy is not currently available. 
 We shall describe some of the pioneer work at Canadian 
Surgical Technologies and Advanced Robotics (CSTAR) on 
Robotics-Assisted Brachytherapy for the potential future 
management of lung cancer. 
SYSTEM AT CSTAR 
 Our work at CSTAR has focused on six areas: i) 
development of a lung tumour model and robotic 
brachytherapy test bed; ii) development of 3D ultrasound 
imaging for lung tumours; iii) design of a delivery system for 
robotic brachytherapy; iv) robotics-assisted brachytherapy 
using the ZEUS platform; v) development of an 
electromagnetic navigation system for precise needle 
insertion; and vi) dosimetry planning. 
 An experimental test bed was developed to assess the 
feasibility of robotics-assisted minimally invasive lung 
brachytherapy when compared to other more traditional 
methods [104-106] (Fig. 2). The system consists of a Video 
Assisted Thoracic Surgery (VATS) box, surgical robotic 
arms, a customized seed injector, an ultrasound machine, an 
electromagnetic tracking system, video monitors, a 
computer, and an endoscope. The ZEUS surgical system 
consists of two arms for instruments. The endoscopic camera 
is held by the AESOP robotic endoscope holder. All three 
arms can be teleoperated by the surgeon from a computer-
based remote console. The instrument arms mimic the 
motion of hand-held instruments, which are manipulated by 
the surgeon from the remote console. Control systems were 
designed for the ZEUS arms that replaced the existing 
controllers in order to provide more accurate and versatile 
control of the motions of the two arms. One of the arms can 
be used to hold and manipulate the ultrasound probe, and 
another to hold and position the seed injector [107]. 
 In this setup, the Aurora electromagnetic tracking system 
(Northern Digital Inc.) was used to track the location of the 
needle and the ultrasound probe. The tiny sensors available 
as part of the Aurora system allowed the placement of the 
sensor at the tip of the stylet inside the needle [106]. 
 In order to use the robotic system to deposit radioactive 
seeds inside a lung tumour within a minimally invasive 
environment when the target tumour is located within the 
lung and thus is not visible, we developed the InterNav3.0™ 
software environment [108]. It incorporates the ultrasound 
image, the information from the electromagnetic sensors, 
and calibration data to provide the user with enough 
information to accurately guide and position a needle at a 
desired target. A Graphical User Interface (GUI) was 
developed as a front end for the InterNav3.0 application. The 
InterNav3.0 GUI consists of several views that provide a 
wealth of information and functionality. Not only does the 
GUI allow the user to visualize the anatomical area of 
interest, it also allows the user to select the appropriate 
target, and provide all of the information required to guide 
the needle towards the target in a quick and intuitive manner 
(Fig. 3). 
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 The robotic arm carrying the seed injector allows the 
position and orientation of the needle to be adjusted inside 
the patient’s body prior to penetrating the target tissue. The 
MIS approach allows better access to organs inside the 
thoracic cavity, and therefore can safely avoid vital 
structures. The injector can easily penetrate the more 
scirrhous tumours, and the remote actuation of the needle 
retraction system reduces the exposure of the clinician to the 
radiation source. 
 A technique for creating intraoperative, near real time, 
3D ultrasound images of human lung nodules using MIS 
techniques was developed [109]. Multiple 2D ultrasound 
images of a subpleural nodule scanned intraoperatively were 
reconstructed into 3D images. We adapted the HDI 5000 
LapL9-5 laparoscopic probe to a transducer holder 
containing a mechanical motor attached to a standard 
computer. The modified probe was used to thoracoscopically 
detect and remove a subpleural nodule through three 12 mm 
incisions. The device was easy to use and the images 
accurately identified the tumour. The images correlated well 
with the preoperative CT scan and final pathology. 
Intraoperative 3D ultrasound proved to be feasible in 
localizing invisible or nonpalpable lung nodules in near real 
time and provided an accurate representation of the anatomy 
during thoracoscopic lung surgery. This is the world’s first 
example of thoracoscopic 3D ultrasound imaging of a human 
lung nodule (Fig. 4) [109]. 
 An ex vivo lung tumour model, using excised porcine 
lung and agar tumours was developed to provide a means of 
verifying 3D ultrasound images and to provide a teaching 
tool for intraoperative lung ultrasound techniques [110, 111]. 
Spherical tumours of various size were made from agar and 
were inserted through incisions on the underside of an 
excised porcine lung. The average coefficient of variation 
and volume error during tumour localization was 11.2% and 
12.9% respectively, and tumour volume error decreased as 
the tumour size increased [111, 112]. 
 Our initial proof of principle experiments demonstrated 
that permanent interstitial brachytherapy seeds can be safely 
and reproducibly inserted using an MIS technique with the 
assistance of the ZEUS robotic system and intraoperative 
ultrasound into in vivo porcine lungs [113]. There were no 
problems with bleeding or air leaks. The ZEUS system 
performed well and was able to remotely manipulate the 
ultrasound transducer and needle to allow deployment of the 
seeds [114]. The ultrasound images were of good quality, 
and provided adequate visualization of the needle insertion 
and seed deployment. There was no evidence of seed 
embolization in the two animals during three months. These 
experiments showed that interstitial brachytherapy seeds can 
be safely inserted into lungs using the ZEUS robotic system 
with 2D ultrasound image guidance. 
 We also compared the accuracy, effort, and time needed 
to place seeds next to a target using a manual method (open 
surgery), video-assisted thoracoscopy (VATS), and the 
ZEUS robot [115, 116]. Our brachytherapy seed injector was 
mounted on the ZEUS system [107]. Four different people 
inserted dummy brachytherapy seeds into clear agar-gelatin 
cubes containing a 1.6 mm stainless steel ball serving as a 
visible target. As anticipated, the open surgery technique 
with manual needle insertion is the most accurate, least 
traumatic (requiring less needle punctures), and the fastest 
method of inserting seeds into tumours. However, the ZEUS 
robotics-assisted brachytherapy was less traumatic and faster 
than the VATS technique. 
 Further experimental results showed that the InterNav3.0 
electromagnetic navigation system improved the 
performance of minimally invasive brachytherapy 
procedures in terms of effort and median tissue trauma, 
while also showing promise in improving the accuracy of 
seed deployment
2
. With manual insertions, the navigation 
system offered no advantage in time, although it led to a 
reduction of the number of attempts and an improvement in 
accuracy. The benefit of a guidance system was manifested 
only when visual information becomes limited in MIS 
scenarios; whereas the intuitive three-dimensional spatial 
perception afforded by the open manual technique has made 
an add-on guiding system seem unnecessary. When 
procedures must be done minimally invasively, however, 
electromagnetic guidance becomes essential. The addition of 
image guidance reduced the average task completion time of 
                                                
2Pytel M, Trejos AL, Patel RV, and Malthaner RA. The InterNav 
electromagnetic guidance system for robotic needle insertion. 2006/1/10. 
Unpublished data. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). MIRA V System showing the three robotic arms holding the seed injector, the thoracoscope, and the MIS ultrasound probe. (Photo 
credit: Meg Woodhouse). 
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one seed insertion by 60 seconds. For the robotic procedure, 
the average time was reduced by 30 seconds. The time saved 
becomes even more significant when more seeds need to be 
inserted. 
 Dosimetry planning was assessed using the Theraplan 
Plus
®
 software and has been found feasible [93]. In an effort 
to realize real time dosimetry replanning as brachytherapy 
seeds are deposited, preliminary software was developed by 
Dr. A. Fenster’s research team. The software accounts for 
actual seed position and recalculates the dosimetry as more 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). InterNav3.0
TM
 user interface showing the Ultrasound View (top left), the position of the target (blue sphere) with respect to the 
needle tip in the World View (top right), and the depth of the needle tip with respect to the target in the Depth View (bottom right). The 
controls for moving the seed injector and dropping the seeds are also part of the user interface (bottom left). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). 3D ultrasound image of a human lung tumour. 
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seeds are deposited (Fig. 5). The software has been modified 
from a template based system for prostate implants to allow 
nonparallel needle insertion that would be necessary in a 
minimally invasive approach. In vitro and ex vivo 
experiments were done to test the performance of the system 
in terms of its ability to optimize the quality of the radiation 
coverage on phantom tumours. 
 Three-dimensional ultrasound scans of phantom agar 
tumours were used for preplanning seed locations. The in 
vitro PTVs covered by at least 100% the prescribed dose 
(V100) was about 97%; that covered by at least 90% of the 
prescribed dose (V90) was about 99%. The minimum dose 
received by 90% of the volume (D90), a parameter that is 
most sensitive to deviations in seed deposition, remained 
high at about 125 Gy (compared to preplan value of about 
145 Gy). The results using ex vivo porcine lungs were 
slightly less accurate, although still acceptable in terms of 
potential for future therapeutic use. The lung brachytherapy 
system performed well in both in vitro and on ex vivo lung 
tissue
3
. 
LIMITATIONS AND FUTURE DIRECTIONS 
 A major limitation to any electromagnetic tracking 
system is the possible distortion in the field by magnetic 
interference caused by the presence of nearby metal objects. 
Improvements in technology have made the current 
generation of sensors less susceptible to such interferences. 
Our experience was that modest amounts of surgical steel in 
the environment do not cause any noticeable deterioration of 
accuracy. However, it would still be important to keep the 
amount of metal to a minimum, and the addition of metallic 
shields could ensure optimal performance. 
                                                
3Lin AW, Trejos AL, Bhatia P, et al. Minimally Invasive Robot-Assisted 
Image-Guided Optimal Dosimetry Planning And Execution Model For Lung 
Brachytherapy. Unpublished data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Image of a dosimetry plan for brachytherapy using 3D ultrasound imaging. (Courtesy of Dr. Aaron Fenster). 
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 The accuracy of brachytherapy seed injection was limited 
by the intrinsic resolution of the ultrasound probe. This 
resolution may be somewhat improved by using a newer 
probe or one with higher frequency (although this would 
have been at the expense of penetration depth). 3D 
ultrasound may hold the key to improved visualization and 
real time dosimetry planning. A better sense of the tissue 
may be obtained through reconstruction of the 3D space by 
piecing together 2D images and their position information. 
CONCLUSION 
 Lung cancer brachytherapy has been advocated for years. 
Recent advances in technology such as robotic assistance 
and image guidance give promise to improved performance 
of minimally invasive lung brachytherapy procedures, 
potentially expanding its clinical role and facilitating better 
patient outcomes. Robotic assistance enables precise 
manipulation of the brachytherapy needle while enhancing 
the ergonomics for the surgeon and radiation oncologist; 
real-time virtual reconstruction of the tissue of interest and 
image guidance allows more intuitive and reliable seed 
deposition. By integrating these two aspects of technology, 
the surgical procedure can be made more automatic, easier to 
learn, less susceptible to user variability, and may translate 
into better treatment efficacy with fewer side effects. 
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